

FIG. 1

BEST AVAILABLE COPY




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8






FIG. 9




**A****B****C**

FIG. 10






FIG. 11



A



B





FIG. 13

FIG. 13 (continued)

C



D





FIG. 14

A



B





FIG. 15

A

**Peptide inhibitors**

Caspase-8 FAM-LETD-FMK, Caspase-10 FAM-AEVD-FMK, Caspase-9 FAM-LEHD-FMK

— Untreated  
— Treated with TRAIL/  
TNF+CHX



FIG. 15 (continued)




FIG. 16




FIG. 17






FIG. 18


A




B



C



D



E





FIG. 19

A



B







FIG. 20 A.



B.






C.

FIG. 20 (continued)

FIG. 21  
A



B







FIG. 22  
A.



B.





FIG. 23

A.



B.






FIG. 24


A.



B.



C.



D.




FIG. 25

6.





FIG. 26.  
**A.**



**B.**




FIG. 27




FIG. 28




FIG. 29

Mouse Experiment

Nude Mice  
injected with  
 $1 \times 10^6$  P.A-1  
cells s.c. after  
11 weeks.



Nude Mice  
injected with  
 $1 \times 10^6$   
P.A-1-IG20  
cells s.c. after  
11 weeks.








FIG. 30




FIG. 31






FIG. 32




FIG. 33





FIG. 34



**FIG. 35**




FIG. 36

40/40

Anti-Fas mAb




FIG. 37



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**